Brian Nowosielski

Global virus and public health experts gathered to assess the need for an enhanced response to the bird flu spreading among humans and animals.

Antonio Ciaccia, President of 3 Axis Advisors, CEO of 46brooklyn Research, and pharmacy benefits expert, discusses the commonly circulated misconceptions about PBMs.

The nation’s largest PBM is placing Novo Nordisk’s premier weight-loss drug atop its formulary beginning July 1, 2025.

In the researchers’ review of data since 1990, they explored the global burden of infertility and the extent in which it is caused by either STIs or maternal sepsis.

Amid record levels of advertisements for lifestyle medications on social media, Luke Turnock, PhD, discusses the global impact these trends may have on patients.

A conversation with Shawn Griffin, MD, FAAFP, President and CEO of URAC, at Asembia’s AXS25 Summit.

A conversation with Harry Travis, BSPharm, President of the Travis Health Group, at Asembia’s AXS25 Summit.

Expert on drug pricing and pharmacy benefits, Antonio Ciaccia joined Drug Topics to discuss how PBMs came to hold so much control of the pharmaceutical supply chain.

Researchers conducted a review of adherence behaviors for patients with dermatological diseases and provided an update on management strategies.

Results are from an open-label extension of a phase 3 trial assessing the pharmacokinetics, efficacy, safety, and immunogenicity of adalimumab-aaty and its reference formulation Humira.

Luke Turnock, PhD, discusses the role of pharmacists and medication counselors in addressing the challenges of increased direct-to-consumer drug advertising on social media.

Researchers explored the confidence, barriers, and role of general practice independent pharmacists regarding prescribing services within primary care settings.

Antonio Ciaccia, President of 3 Axis Advisors, CEO of 46brooklyn Research, and pharmacy benefits expert, discusses litigious, market-based, and legislative reform for pharmacy benefit managers.

Researchers identified differences in naloxone training, policies, procedures, and preferences among chain or independent pharmacies across Alabama.

Leveraging his expertise in pain management, Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, joined Drug Topics to discuss the importance of pharmacists in patients’ use of OTC medications to treat pain.

Expert in drug markets, Luke Turnock, PhD, joined Drug Topics to assess where he thinks recent trends in drug advertising will lead patients in the near-to-long-term future.

Researchers explored whether or not hormonal contraceptive initiation is associated with increased risk of developing depression within 12 months of child delivery.

CVS releases a statement shortly after HB1150 was signed in Arkansas, prohibiting pharmacy benefit managers from owning pharmacies.

Researchers conducted an observational cost analysis of dermatology drug savings between GoodRx and Mark Cuban Cost Plus Drug Company.

Researchers explore trends from 2014 to 2022 among pediatric invasive pneumococcal diseases since introduction of the 13-valent pneumococcal conjugate vaccine.

Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, discusses trends in over-the-counter pain medications amid the ongoing opioid emergency in the US.

From 1990 to 2021, researchers explored the global burden of atopic dermatitis among older adults.

Luke Turnock, PhD, MSc, discussed current trends in the promotion of lifestyle enhancement drugs for populations they are not approved for.

Researchers conduct a review to understand the efficacy and safety of topical minocycline for the treatment of moderate to severe papulopustular rosacea.

LucyRx is empowering pharmacists and impacting patients’ health outcomes with its business model unlike other market-leading pharmacy benefit managers.

The 14-section order focuses on a variety of policy changes intended to make patients’ out-of-pocket costs for prescription medications more affordable in the US.

Over 20 years since skin of color dermatology was introduced, researchers explored advancements and what is yet to come in the future.

Pain expert Mark Garofoli, PharmD, BCGP, CPE, CTTS, discussed the pharmacist’s role in managing patients’ use of OTC pain relief products.

On behalf of 39 state and territory attorneys general, the National Association of Attorneys General issued a letter to Congress regarding major PBMs’ conflicts of interest.

David Blair, CEO of LucyRx, joined Drug Topics to discuss the initiatives his company is conducting in support of a struggling pharmacy profession.